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Abstract
In silico models have prompted considerable interest and debate because of their potential value in predicting the
properties of chemical substances for regulatory purposes. The European REACH legislation promotes innovation
and encourages the use of alternative methods, but in practice the use of in silico models is still very limited. There
are many stakeholders influencing the regulatory trajectory of quantitative structure-activity relationships (QSAR)
models, including regulators, industry, model developers and consultants. Here we outline some of the issues and
challenges involved in the acceptance of these methods for regulatory purposes.
Introduction
The concern to protect human health and the environ-
ment has prompted significant change in EU regulation
on chemical substances. The REACH legislation requires
industry to evaluate the toxicity not just of new chemicals,
but of the tens of thousands of existing chemical sub-
stances that are in use but have never been subject to reg-
ulatory testing. Many argue that to achieve this by
traditional testing would take decades, cost billions and
consume many millions of vertebrates. It is therefore sig-
nificant that the legislation explicitly encourages innova-
tion in toxicity evaluation, demands the use of existing
data where possible, and states that further animal testing
can only be used ‘as a last resort’.
In this context, in silico models are potentially invaluable
because they use computer technology to connect, use and
extend existing experimental data, and can be used to
assess thousands of chemicals quickly. The REACH legis-
lation sets out conditions specifically for the use of
QSARs, and the European Chemicals Agency (ECHA), in
its role in implementing REACH, offers detailed guidance.
Even the basic ‘Guidance in a nutshell’ on substance regis-
tration advises industry to ‘collect QSAR estimated results
for the substance if suitable models are available’ as an
initial step [1].
However, in practice, the use of in silico models
within REACH by European industry is still very limited.
In moving forward, the current focus is therefore on the
highly inter-connected issues of
(i) acceptance by regulators (ECHA and the national
competent authorities),
(ii) uptake by industry and consultants, and
(iii) the progress of model developers in designing
and developing models specifically for regulatory
use.
It is now clearer to developers and users what is
expected of in silico models for regulatory use. The reg-
ulatory framework of REACH, the OECD principles and
the ECHA guidelines effectively work together to
increase the demands on models in terms of rigour,
reliability and transparency. Yet despite progress, there
are still inevitable limitations in terms of
(a) the models currently available,
(b) the experience of using models for regulatory
purposes, and
(c) the experimental data available for developing
new models for particular endpoints.
Current policy is therefore that the use of in silico
models will be accepted or rejected by EU regulators
strictly on a case-by-case basis, following regulatory
review that examines the details of the models used and
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intention seems to be to avoid a situation in which indivi-
dual successful and unsuccessful examples of using in
silico models could be over-generalised as indicative
‘good’ and ‘bad’ case studies.
An important way forward in developing a wider
understanding of QSARs for regulatory purposes is
therefore to step back from citing individual examples,
and instead to elaborate and increase understanding of
the often-complex issues around model development,
use and acceptance. That is our focus in this paper.
The three primary stakeholder groups in this process
(regulators, industry and consultants, and model develo-
pers) each has particular priorities and concerns, and
particular expertise to bring to the debate around the use
of in silico models. At the same time, their institutional
requirements, and existing practices, may inevitably cre-
ate important barriers to the further use of in silico mod-
els. Dialogue and shared understanding are therefore
vital. Moreover, these primary stakeholders operate
within a wider stakeholder context in which the interest
(or lack of interest) from toxicology research commu-
nities, industry managers, shareholders, non-governmen-
tal organizations (NGOs) and citizens may be highly
influential. A range of issues is intrinsically involved.
Before describing some of those issues, it is useful to
foreground the basic issue that expertise, functionality
and judgement are central to regulatory toxicology,
including the use of in silico models.
In silico models are usually developed by scientists,
potentially across the fields of toxicology, chemistry,
engineering and computer modelling. They are also
developed for particular purposes, including academic
research and industrial product development, and are
produced both from government research funding and
commercially. In the US, Canada and Denmark they have
been widely developed by regulators.
The challenge for developers is to produce models that
are not just ‘scientific’, but also functional and ‘fit for
purpose’ within the regulatory context. The regulation
inevitably makes demands on the scientific evidence that
must be provided by industry to support claims that the
safety and toxicity of a chemical have been measured and
are known. Decisions in the design and acceptance of in
silico models for regulatory purposes therefore have to be
oriented to an understanding of regulatory as well as
scientific aspects.
As with the historical case of defining geographical
coordinates, the development of rules proceeds through
a combination of scientific and political judgements. So
thresholds may vary according to different regulations,
and in different countries.
Regulatory thresholds and criteria also involve techni-
cal judgements, not just in terms of the numerical value,
b u ti nt h ew a yt h a tn u m e r i c a lv a l u ei sm e a s u r e do r
expressed. For instance, for classes of aquatic toxicity
defined for regulatory purposes the units are typically
expressed as concentrations measured as weight per
volume. Yet it is more usual for scientists to refer to the
toxicity process in terms of moles per unit of volume,
because the toxicity is assumed to be related to the mole-
cule itself; thus, it seems more appropriate to use mmol/l
instead than mg/l. This example simply illustrates that
many technical judgements can also be involved in the
setting of a threshold or criterion, and in the evaluation
of an in silico model.
Complex technical expertise, evidence and judgement
similarly form the basis for an in silico model. In obser-
ving and modelling the relationships between the mole-
cular structure of carbon-based chemicals and their
biological activity, both sides of this relationship are com-
plex and multi-dimensional: there are thousands of ways
in which a substance and its molecular structure can
potentially be described, and many endpoints involve
complex and sequential biological processes. There is
also a range of technical factors that form the basis of an
in silico model and determine its rigour and reliability.
They include: the number and nature of the chemicals
which are used to build the model; the nature of the
observed property for this series of chemicals; the quality
of the available experimental data; the way the chemical
structures are described (e.g. SMILES or sdf file); the
range of chemical information used for modelling pur-
poses (such as chemical descriptors, or fragments); the
mathematical algorithm at the basis of the model; the
ways in which the developer checks the statistical charac-
teristics of the model; and the ways in which the model
expresses predictions and enables the user to identify
associated uncertainties. The factors involved in the
development of in silico models for regulatory purposes
are discussed by Benfenati [2].
Given the range of endpoints, the vast numbers of che-
micals, the large palette of mathematical algorithms avail-
able, and the potential to use tens of thousands of
chemical fragments and thousands of chemical descriptors
to build a predictive model, it is clearly possible for future
scientists to generate huge numbers of in silico models. It
is easy to imagine an explosion in the number of useable
models, many with quite similar performance.
Discussion
The regulatory conditions for the use of QSAR models
In developing, using and discussing in silico models for
regulatory purposes, it is necessary to start by recognising
the requirements which have been defined by law. It is
necessary to address a specific regulation, since different
principles may apply to different regulations. Here we
will refer to REACH, the European regulation for the
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Chemicals [3]. This means that certain assumptions may
not be valid for other regulations.
REACH explicitly refers to in silico models, including
quantitative structure-activity relationships (QSAR) and
structure-activity relationships (SAR) models. (Other in
silico models exist, such as those used for virtual screen-
ing, in which a ligand molecule is bound to a natural
macromolecule through specific programs [4].) Below
we will use the term QSAR to refer to both QSAR and
SAR models.
According to REACH regulation (Annex XI) a ‘(Q)
SAR is valid if:
￿ the model is recognised as scientifically valid;
￿ the substance is included in the applicability
domain of the model;
￿ results are adequate for classification and labelling
and for risk assessment;
￿ adequate documentation of the methods is
provided.’
These four ‘conditions’ address important scientific and
practical aspects of the use of in silico models, including
those specific to the application. We discuss each of
these below (in a different sequence).
The four conditions are also specific to the regulatory
context. For example, from a scientific point of view a
model can be a good model even if full documentation is
not provided. Similarly, industry develops models for its
own purposes, using algorithms and data which are
restricted and confidential, intended for endpoints which
differ from those of interest within REACH; these models
might be scientifically correct but are inappropriate for
REACH purposes.
Adequacy for classification and labelling and for risk
assessment
The condition of adequacy (the third listed above) states
that to be acceptable for use within REACH, the results
from a QSAR model must be ‘adequate’ for the particular
regulatory function. This condition has also been
described as requiring that ‘the prediction should be fit for
the regulatory purpose’ [5]. Classification and labelling
(C&L) and/or risk assessment (RA) are the two uses iden-
tified, though a third use is the prioritisation of substances,
(addressed by REACH in Article 44). Thus QSAR models
can be used for three different uses or purposes within
REACH.
These three regulatory uses can each require the use
of different QSAR models, because different endpoints
are addressed, and because different levels/kinds of cer-
tainty are required. This fact has not been discussed in
detail so far, and needs wider attention.
Most attention has naturally been given to the use of
QSAR models to provide values for the registration of sub-
stances. This is one of the most important aspects, com-
pared to the other possible uses, and in general, risk
assessment (RA) evaluation is requested for higher ton-
nage chemicals. RA can require continuous values, in
order to calculate the mathematical ratio between the
t o x i cd o s ea n dt h ee x p o s u r el e v e l .W et h e r e f o r eh a v et o
remember that some models, especially for human toxi-
city, do not provide continuous values, so in such cases of
substance registration where continuous values are
required, the use of QSAR models can be limited.
The demands for C&L contrast with those for RA in
several important respects. Firstly, different endpoints
have to be addressed for C&L, secondly, a yes/no classifi-
cation requires less accuracy in terms of the relationship
between toxicity and dose levels, and thirdly, within
REACH C&L is carried out on the basis of the information
available. There is therefore potential for a significantly
wider use of QSAR models in the evaluation of chemicals
where there is a lack of existing data for C&L. Arguably,
all chemicals could be assessed using the available models,
and this would probably increase the safety of those
chemicals.
For C&L and RA, the nature of the QSAR model
required may be different in many cases. C&L involves
creating a classification of whether a chemical is toxic or
not for a particular endpoint, so it requires classifier mod-
els. Yet this distinction in terms of what is required is
more complex than it appears. Even for QSAR models
which are typically classifiers, such as those used to predict
carcinogenicity, it may be more appropriate and useful to
have a quantitative evaluation of the potency, because if
the chemical is carcinogenic then it is important to be able
to evaluate the risk at a given dose level. Moreover, for
certain endpoints, whether a continuous value or category
value is required by REACH, depends on the tonnage of
use on the market. For example for the bioconcentration
factor endpoint, only the simple classification (of bioaccu-
mulative or not) is required for lower tonnage chemicals,
while a continuous value is required for higher tonnage
chemicals (above 100 tonnes/year).
In the third regulatory use of QSAR models, for priori-
tisation, the situation appears to be more straightforward.
Neither the lower number of endpoints of interest, nor
the potential uncertainty of the results, is critical, because
the goal is to determine which chemicals require higher
scrutiny.
The implications in terms of evaluating the adequacy of
a QSAR model is that we must always be very clear about
the regulatory purpose for which it is being used and the
relevant regulatory requirements. A given QSAR model
may be adequate and very suitable for a specific use within
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unsuitable for a different use.
Providing documentation of the methods
REACH requires detailed documentation to be sub-
mitted by the registrant of a substance. If QSARs are
used, this documentation needs to include details of (i)
t h eQ S A Rm o d e l sa n dt h ed a t as e t st h e ya r eb a s e do n ,
and (ii) the ways in which the models have been used to
assess the toxicity/safety of the target chemical. The
intention is that the documentation should enable the
regulator to conduct an independent and informed eva-
luation of the chemical safety evidence provided.
Hypothetically, we might imagine a model which erro-
neously predicts certain compounds to be safe, because
i tw a sd e s i g n e dt od ot h a t( i no r d e rt oa l l o wt h eu s eo f
a certain compound on the market). If the model details
are not made available (perhaps for confidentiality
issues) the regulator would be unable to identify the
false predictions. A clear priority for regulation is to
avoid the possibility of such a scenario.
In a more realistic scenario, it is possible that two mod-
els could give opposite predictions for the same chemical.
If the two models were confidential, it would not be pos-
sible for either the user, or the regulator (or even a peer
reviewer) to determine why the two models had pro-
duced opposite results. However, if the appropriate docu-
mentation is available it may then be possible to identify,
for example, that while one model was built on a training
set of compounds that are similar to the target chemical,
the second model was not.
In this way, the reliability of a model, and the authority
of its predictions, depend on its transparency. The issue
of providing ‘adequate documentation of the models’ and
their use, is central to demanding and ensuring the qual-
ity of models and the quality of their use, now and in the
future. It is ultimately about enabling the regulator to
evaluate chemical safety assessments in the interest of
human health and the environment.
In our experience it is actually preferable for more than
one model to be used, and for the user to analyse how
the models work in order to understand the potential sig-
nificance of any difference in their predictions for a target
chemical. (The example of two models with different pre-
dictions, above, illustrated the issue of whether the target
chemical was within the applicability domain of the
model, explained below.) With large numbers of QSAR
models now available within and across the main plat-
forms, and with the fast processing of chemical data
made possible by QSAR technology, the use of several
models is feasible in practice as well as advisable.
In the case of commercial software, the full documen-
tation of each model is typically not available. Indeed, the
algorithm and the training set used to build the model
are often confidential. Despite this, the use of commercial
programs has not been explicitly criticised by regulatory
authorities. In reality, commercial programs have been
used in the USA and Europe, because of their ease of use,
their availability and because they represent a major
s o u r c eo fQ S A Rm o d e l s .W ed on o tf o r e s e er e s t r i c t i o n s
i nt h e i ru s e ,a n di no u ro p i n i o ni tw o u l db eap i t yt o
renounce these models. However, it is likely that in the
case of two similar models being available, one commer-
cial and one freely available, the user will prefer the sec-
ond one. Within REACH, it also seems likely that the
regulators will demand more transparency from the com-
mercial models, and/or prefer the use of fully documen-
ted models.
Inclusion within the applicability domain
The REACH legislation does not list a series of ‘approved’
QSAR models, and ECHA does not intend to. The pur-
pose of REACH is not to define QSAR models, but to reg-
ister, evaluate, authorise and restrict chemicals. REACH
states in broader terms that the validity of QSAR models
must be characterised and documented. The ECHA gui-
dance suggests this be done by referring to the five agreed
OECD principles. One of these principles is that ‘The (Q)
SAR model should be associated with a defined domain of
applicability’ [5]. The term ‘domain of applicability’ refers
to a defined set or range of chemicals for which the model
is intended to be used.
The related condition for using a QSAR model within
REACH (that ‘the substance is included in the applic-
ability domain of the model’) therefore builds on this
principle in practice. In effect it requires that
(i) each model being used has a clearly defined
domain of applicability, and
(ii) this has been followed in practice, so that the
chemical being evaluated actually lies within the
range of chemicals for which the model was
designed and intended.
Every user of QSARs has to be aware that QSAR
models are only appropriate and reliable for specific sets
of chemicals. A highly reliable model will not produce
reliable results for chemicals that lie outside the domain
of applicability.
This basic issue is true to varying degrees for all meth-
ods of toxicity evaluation. Within REACH the concern is
to protect human health and the environment, so even
traditional animal tests are actually only surrogates or
models; their reliability depends on testing relevant
effects in relevant animals and anticipating relevant bio-
logical and environmental processes. As history has
shown, such tests do not provide certainty about the ulti-
mate effects of a chemical on human beings or the
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acknowledge that all results bring uncertainty, and to
recognise and understand the strengths and potential
weaknesses of the particular approaches being used. In
the case of QSAR models, a clear strength is the ability to
make use of literally thousands of experimental results to
both build and test the model, and to be able to select
from the thousands of potential descriptions of the che-
mical substances those descriptors which most accurately
correlate with the observed toxicity. But the inevitable
limitations come from the reliability of those initial ani-
mal tests, from the rigour within the model development
and review process, and from the similarity of the target
chemical to those tested.
Hence the use of experimental models, and QSAR
models, requires an initial evaluation of their correct
application for the situation of interest. A question that is
frequently asked by potential users of QSAR models is
whether they can be used for a particular compound.
This vital evaluation is addressed by the applicability
domain (AD). Some tools even have been developed to
advise the user. However, most QSAR methods use the
‘chemical space’ of the chemicals in the training set, and
evaluate whether the target chemical is similar to these in
relevant ways (the chemometric approach) [6]. A more
complex approach has been developed for the CAESAR
models [7]. In this case, the evaluation of whether the
model is appropriate for a particular target chemical is
based on the accuracy of the predictions produced by the
model for compounds that are similar to the target com-
pound, and for which there are experimental results.
(It should be noted that not all QSAR models include
an explicit applicability domain. In some cases the AD
cannot be addressed for intrinsic reasons. This may be
the case for models which search for molecular frag-
ments which have been identified as producing toxicity,
from current biological understanding. Such models typi-
cally do not refer to a training set of compounds, even
though the list of toxic fragments is inevitably incom-
plete. Thus, if models like Derek or Toxtree produce the
result that no toxic fragment is identified, we cannot
then infer that the target chemical has no toxicity; the
negative result may be due to lack of current knowledge
on the toxic fragment. Such models have inevitably been
criticised for this limitation.)
The scientific validity of the model
We started this paper by stating that many technical
factors form the basis of an in silico model and deter-
mine its rigour and reliability, such as the number of
chemicals in the training set, the quality of the data, the
chemical information, and the algorithm. We have also
observed that requirements from REACH impact on
this evaluation, and different criteria apply for different
uses, and different levels of reliability may be demanded
for different chemicals for several important reasons.
In its guidance for industry and regulators, ECHA states
that the validity of QSAR models for regulatory purposes
is ‘characterised and documented according to the five
agreed OECD principles’ [5]. These principles were
adopted by the OECD in 2004, after exploring the com-
plexity of factors involved in the regulatory evaluation of
QSAR models [8]. The principles were intended to antici-
pate a range of potential regulations, so it is important to
note that they were not related to REACH and the legisla-
tion itself does not refer to them. However, in the imple-
mentation of REACH, ECHA and others usefully refer to
them. As ECHA’s guidance reports [9] the OECD stated
that ‘to facilitate the consideration of a (Q)SAR model for
regulatory purposes, it should be associated with the fol-
lowing information:
1. a defined endpoint;
2. an unambiguous algorithm;
3. a defined domain of applicability;
4. appropriate measures of goodness-of-fit, robust-
ness and predictivity;
5. a mechanistic interpretation, if possible.’
While these OECD principles address the qualities of
QSAR models, ECHA focuses on the quality of their use
in practice. ECHA emphasises that:
The principles constitute the basis of a conceptual
framework, but they do not in themselves provide cri-
teria for the regulatory acceptance of (Q)SARs. Fixed
criteria will be difficult, if not impossible, to define in
a pragmatic way, given the highly context-dependent
framework in which non-testing data will be used.
Instead, experience and common understanding
should be gained by a learning-by-doing approach,
and by documenting the learnings...[9]
This caveat illustrates the policy of ECHA that the use
of QSAR models must be evaluated by industry and regu-
lators ‘on a case-by-case basis’ [9]. As we have said, the
validity of predictions depends not only on the scientific
quality of the models used, but also on the regulatory
function and the target chemicals that they have been
used for, and on how they have been used.
In this way, REACH does not refer to validated mod-
els, but instead to the use of a valid model (Annex XI).
Acceptance is not of the model, as something univer-
sally valid, but of its use for a certain regulatory function
and chemical substance. (Moreover, with potentially
thousands of QSAR models, an official validation pro-
cess would take years and be constantly out-of-date in
the evolving technology.)
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quality of use in practice (already described above)
include whether the particular target chemical is within
the applicability domain of the model, whether the end-
point, algorithm, data sets and applicability domain are
actually documented to support the prediction, and
whether the model predictions are adequate in practice
for the specific regulatory functions of risk assessment
and classification and labelling.
The OECD emphasis on the statistical evaluation of
QSAR models is worth noting. (ECHA guidance also
articulates principle 4 as the ‘appropriate performance
of the model (the statistical “goodness” of the model,
robustness and predictivity)’[5].) This statistical focus
addresses the functional shift from using QSARs for
scientific exploration to using them for prediction in the
regulatory protection of human health and the environ-
ment. Documents from the OECD [8] and ECHA [10]
highlight the need to use models which have a sound
statistical basis both in terms of the model development,
and (for particular sets of chemicals and a particular
endpoint) in terms of the proven quality of their
predictions.
Most early QSAR models were interested in the
description of a particular phenomenon, and in the
explanation of the physico-chemical factors involved. At
that stage, the aim was not to predict the biological
activity of compounds outside the set of the chemicals
used to build the model. Instead, the aim was to under-
stand whether certain parameters were related to the
observed phenomenon within that set of chemicals.
Typical examples are the models for aquatic toxicity, in
which toxicity was correlated with logP (the logarithm
of the partition coefficient between octanol and water).
The central issue is that a scientifically plausible
model is not necessarily a predictive model. The current
interest in developing and using QSAR models to pre-
dict the property value of chemicals, and in using them
where possible to replace traditional experimental mod-
els, rightly brings new demands for evidence of the
model’s predictive reliability and of its relevance to the
target chemical. In other words we take Galileo’sl e s s o n
to provide experimental evidence of a theory; including
of each claimed relationship between molecular struc-
ture and biological activity.
Interestingly, if a model developer uses a range of
descriptors to create a perfect fit between structure and
observed activity for the initial group of chemicals with
known experimental results (the ‘training set’), this can
result in the model producing poorer predictions for
other related chemicals. So developing a model for reli-
able prediction requires a slightly different approach.
Then to evaluate the model, it is necessary to test
whether it can make accurate predictions for chemicals
that were not used to develop the model, but for which
experimental measures of toxicity are available (a ‘test
set’). The prevalence of active (toxic) and non-active
compounds in the training set and test set is of course
important. (The methodologies for performing internal
and external validation are available in the literature
[2].)
When evaluating a model, it is clearly important to
address the regulatory significance of errors in predic-
tions, rather than simply their size. For example, while
the under-prediction (false negatives) and over-prediction
(false positives) of toxicity may appear equivalent from a
purely statistical point of view, these two types of errors
are not equivalent for the regulator, industry or citizen.
Regulators want to avoid evaluating a toxic chemical as
safe, yet the opposite error is less critical. They therefore
generally prefer a conservative model. Conversely for
industry, an error which wrongly predicts a chemical to
be toxic (false positive) represents a potential economic
loss.
Typically, QSARs for risk assessment are regression
models which use statistical evaluation based on the
errors squared. This does not distinguish between over-
and under-estimations. Only a few models have so far
taken this into account: those developed within the pro-
jects DEMETRA [2] and CAESAR [7,11-15] gave differ-
ent weights to under-estimations when building the
models. However, for QSAR models designed as classi-
fiers, it is common to evaluate separately the specificity
and sensitivity, or the false positives and false negatives,
so the evaluation is useful when selecting a model for a
particular regulatory purpose.
The evaluation of whether or not a model is capable of
correctly predicting the toxicity of chemicals is of course
also addressed within the issue of the applicability
domain. But once again we see the complexity, and how
different aspects are linked. In case of the predictivity,
the evaluation is on the basis of the quality of predictions
for a population of chemicals. In case of the AD analysis,
REACH asks whether the model is reasonable for a speci-
fic substance. Other aspects can therefore be included in
that AD analysis, which are not statistical. An AD can be
formulated also on the basis of certain chemical moieties
present in the molecule, and/or from an interpretation of
the mechanism of toxicity for the chemical of interest.
The term ‘mechanistic interpretation’ refers to a cur-
rent scientific interpretation of the mechanism by which
the chemical produces the biological activity. The OECD
recognised that it was not always possible, so added ‘if
possible’ to the fifth principle. It seems worth noting that
REACH does not mention it. ECHA merely requests that
any mechanistic associations between the descriptors
used in a model and the relevant endpoint be
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dence in the model’ [9].
The importance of a mechanistic interpretation is a
point of debate. Some stakeholders involved in the use of
in silico methods see it as vital in providing a scientific
rationale both for grouping a set of chemicals in terms of
the particular endpoint, and for justifying why the target
chemical is related to them. Others, including ourselves,
argue that the highly complex nature of molecular struc-
tures, and the highly complex and sequential nature of
biological and environmental toxicity, inevitably mean that
any mechanistic interpretation is only a current hypoth-
esis. We argue that it is important to base QSAR models
and predictions on demonstrable correlations between
measured toxicity and molecular qualities, rather than lim-
iting these models to the few cases where there is scientific
knowledge of the toxicity mechanism.
Clearly, stakeholders can feel more confident in a pre-
diction of toxicity if, for example, we can see that a num-
ber of chemicals have the same toxic fragment that is
present in the target chemical. Similarly, we may recog-
nise that a scientifically plausible toxic mechanism of
action is likely, due to the presence of a certain chemical
moiety in the molecule. Yet it is vital to realise that these
assumptions do not represent certainty for a given
mechanism, or for toxic activity in the target chemical;
they are merely useful indications that this is likely to be
the case. The mere presence of a certain toxic fragment
is not conclusive. There may be chemicals which contain
the fragment but do not show toxicity: for example, the
toxic fragment may not be accessible due to steric fac-
tors, and/or other components in the molecule may pre-
vail and result in a detoxification process.
While certainty is not achievable from any model
(including experimental models), we argue that in order
to provide a better appreciation of the probability of a
particular toxicity, it is vital to generate a sound statistical
analysis of exactly how many chemicals with a certain
toxic fragment (for example) are really toxic, and how
many are not toxic. A statistical analysis can provide a
probability of toxicity for a particular chemical, and so
provide a quantitative basis for assessing risk. It also pro-
vides a basis for further investigation of the complex fac-
tors producing the toxicity.
The needs of different stakeholders and barriers to the
use of QSAR models
The preceding discussion has indicated some of the rea-
sons for the current limited use and acceptance of QSAR
models in practice within REACH, and the challenges.
Clearly, different stakeholders have different needs in
relation to increasing the use of QSAR models. In a sepa-
rate paper (forthcoming) we report an initial investiga-
tion and analysis of these barriers and needs. Here, we
focus on some core issues from experience and discus-
sions with stakeholders, in order to help all stakeholders
to recognise the commonalities, differences and
challenges.
There are at least seven reasons to use QSAR models
and other in silico methods within REACH:
1. Innovation in the evaluation of toxicity is encour-
aged by the REACH legislation; the development of
alternative methods is given as one of the purposes
of REACH.
2. The time necessary to produce the data requested
under REACH for tens of thousands of existing che-
micals would be very long if in vivo approaches were
used, probably decades; however, where sufficient
experimental data sets are already available from in
vivo or in vitro tests of related substances, then in
silico methods can be used to assess thousands of
chemicals in a day.
3. There is a lack of laboratories in Europe capable
of performing in vivo tests for such large numbers of
substances; conversely in vitro tests require less
investment, and in silico methods can be employed
on an office computer.
4. The costs of carrying out these evaluations with in
vivo methods would be billions of Euros; alternative
methods, and especially in silico methods, are cheaper
by orders of magnitude.
5. If in vivo methods were used, the evaluations
would consume many millions of vertebrates; alter-
native methods can r e d u c eo rr e p l a c et h eu s eo f
animal testing;t h i si sn o to n l yas t a t e dp r i o r i t yo f
REACH for regulators and industry, but it is also
increasingly desired by industry shareholders, man-
agers and consumers, and by citizens and their
representatives.
6. In silico methods offer tools for the prioritisation
of chemicals according to their predicted toxicity.
This means that the time delays, economic costs and
use of vertebrates can all be reduced by simply target-
ing the use of traditional in vivo tests on those sub-
stances which have the highest probability of toxicity
and higher risk.
7. The predictive ability of in silico methods enables
a proactive approach within product development
and regulatory toxicology. Toxicity evaluation can be
brought ‘upstream’ in the product development and
decision making processes, so that chemicals are
selected and products developed to be non-toxic
from the beginning, rather than the adverse proper-
ties being revealed only late in the process, with eco-
nomic and other consequences.
Regulator interest in the use of QSAR models is
prompted and encouraged by the explicit promotion of
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toxicity within the REACH legislation. This is made
clear in the first article of the legislation, and comes
from a regulatory awareness both of the limitations of
traditional methods and of the new possibilities created
by toxicology research in recent years. Given that the
priority of REACH, and the focus of ECHA and national
regulatory authorities, is to protect human health and
the environment, then the issue for all is how to com-
bine and use methods of toxicity evaluation in order to
achieve it.
REACH and ECHA actively encourage industry regis-
trants to use the range of different sources of informa-
tion available, and to integrate these within a ‘weight of
evidence’ approach. In this way, QSAR models can be
used both as an alternative and a supplementary source
of information. Their use as an alternative source and
only source of information is possible when the reliabil-
ity of the results is sufficient. Their use as a supplemen-
tary source is possible when further information or
confirmation is needed from other sources.
It is often valuable to use more than one model, based
on different descriptors, algorithms or approaches, so that
the results can give different perspectives and so contri-
bute to the assessment. Several articles have shown that
consensus approaches yield better predictions [2,16-18].
We suggest that regulators should encourage industry to
exploit as many appropriate QSAR models as possible, in
order to comply with the REACH demand to generate the
most information for each chemical while avoiding the
unnecessary use of animals. Depending on the purpose,
different kinds of models may be suitable, and different
levels of uncertainty may be acceptable (as discussed
above) in achieving the over-riding priority of protecting
human health and the environment.
For each use of a QSAR model, regulators need, and
require, the information we have outlined and discussed
in the previous sections. This includes transparency in
the model, clarity in its intended endpoint, applicability
domain, predictions and associated uncertainty, and
above all, information that directly addresses the regula-
tory demands.
Looking ahead, in this period of rapid change, national
regulators also need to be kept abreast of developments
within and beyond Europe. For instance, the Tox21 [19]
and ToxCast [20] initiatives in the USA are involved in
screening thousands of chemicals for toxicity and are
expected to reshape the toxicological procedures for the
evaluation of chemicals. By providing up-to-date data for
thousands of chemicals, they will increase the need for in
silico models, in order to analyse and make full use of
that data for future evaluations.
Industry in Europe now faces an urgent need to pro-
vide toxicological data on their existing and new
substances in order to maintain a market for their pro-
ducts and sustain their economic interest. The ultimate
threat from REACH is simply ‘no data, no market’.T h e
potential to use cheaper and faster methods of toxicity
evaluation is therefore extremely attractive to many in
industry. Yet they also need to be sure firstly that the
evaluation will be accepted by regulators, and secondly
that their evaluation is reliable so that they maintain the
quality and reputation of their products as safe. If it is
uncertain whether regulators will accept a QSAR predic-
tion, then industry will prefer to use a traditional experi-
mental method in order to avoid uncertainty and delay
in regulatory approval. Similarly, if those in industry
themselves lack confidence in the prediction, they may
again prefer to stay with a traditional experimental
method. Thus, the position of industry on using QSAR
models can be both different to that of regulators, and
closely related to the acceptance by regulators.
It is important for all to recognise that QSAR models
compete with the more standardised in vivo methods,
where the procedures are very clearly defined in official
protocols. Even though the in vivo tests contain uncer-
tainty, there is evident confidence from years of experi-
ence that they will receive regulatory acceptance if it is
shown that the official protocol has been followed. The
level of uncertainty for industry in achieving regulatory
approval is therefore currently lower if traditional meth-
ods are chosen rather than QSAR models.
There is also currently far less knowledge in industry
about QSAR models than about traditional experimental
methods. Much more dialogue and training is necessary
to build understanding and confidence. This needs to
explain what is possible with QSAR models, but also
address the limitations. Honesty is vital if the technology
is to be understood and trusted, and if potential users are
to be able to judge how to use it wisely.
Consultants are in a potentially central role in terms of
whether innovation and the use of alternative methods
actually happen in practice. While large companies have
their experts and laboratories in-house, small and med-
ium enterprises usually rely on consultants for the eva-
luation of the toxic properties and environmental issues.
Consultants usually have a background in toxicology and
provide small companies with vital advice and informa-
tion. However, in many cases they have access or links to
laboratories which do animal experiments, and as a
r e s u l t ,t h e r em a yb eat e n d e n c yt ob es c e p t i c a la b o u t
alternative methods, and a potential conflict of interest
may result in a preference for using animal models. This
needs be taken into account by regulators and others
when reviewing the positions, needs and interests of dif-
ferent stakeholders.
Model developers (scientist and engineers) are in
the professional role of exploring and developing new
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scientific research, those developing QSAR models for
regulatory use need to recognise that their focus is the
specific regulatory application of the more general
QSAR methodology. Developing scientific models with-
out first developing a detailed knowledge of the specific
regulatory requirements will lead only to frustration.
In practical terms, it is useful for a developer to turn
the REACH and ECHA demands into a check-list of
actions, so that the model specifically addresses the reg-
ulatory demands. In most cases this will help in devel-
oping the explicit scientific rigour and reliability of the
model. Any lack of documented information about a
model is simply a guaranteed barrier to its acceptance.
Models should be as transparent as possible, in terms of
the explanation of the model, its subsequent use, and
the clarity of the result.
Developers of QSAR models clearly have their own
interests, needs and desire for recognition. But the shared
goal among developers has to be to produce a broad pal-
ette of different, but focussed, applications. Given the
value of using more than one model in an evaluation
(discussed above) developers should not see their models
as being in competition with those created by others. Dif-
ferent models, especially if they are based on different
assumptions and approaches (such as on the basis of
toxic fragments chemical descriptors or statistical meth-
ods) can increase the confidence in the QSAR prediction
if the predictions agree. If they disagree, an evaluation of
the reasons can provide the user with insights for the
assessment of the chemical, and help to define the uncer-
tainty of the results. In both cases, the value and contri-
bution of QSARs is strengthened by the complementary
use of different models. It is therefore important for
developers not only to engage in constructive peer
review, and to draw understanding from potentially dif-
ferent predictions, but also to avoid merely criticising the
methods of other developers in order to promote their
own method or seek recognition. This will bring confu-
sion and reduce general acceptance. We are in a positive
scenario where models are available, cheap and fast to
use, and can be used in combination, so the potential for
difference and complementarity between models
becomes a strength and an asset for all.
Citizens and NGOs who are active in the protection of
animal rights will favour QSAR models for reducing ani-
mal testing, albeit also partly relying on animal testing.
Citizens associations more widely can benefit from the
accessibility and facilitated use of QSAR models because
these models may offer ways to investigate the adverse
effects of substances. Clearly, the use of predictions from
QSAR models by any stakeholder requires some under-
standing of what makes them reliable.
Future directions
QSAR models now and in the future may prove to be an
increasingly valuable technology, with a potentially
important function for protecting human health and the
environment. It is therefore vital to avoid the familiar tra-
jectory of a developing technology being initially over-
stated in terms of its capabilities, and then discredited
when it is over-applied. It is in the interests of all stake-
holders that QSAR models are explained openly and
used appropriately with care.
Our intention in this paper has been to elaborate
and increase understanding of the seemingly complex
issues around model development, use and acceptance
within REACH. Our aim is to generate debate and
understanding among and between the different stake-
holders, as a way of exploring how stakeholders can
benefit from QSAR models and can together increase
the regulatory use and acceptance of QSAR models in
practice.
As the previous sections have shown, ongoing debate
and understanding need to look beyond the technical
issues in using QSAR models, to the other significant
challenges raised by their regulatory use. Discussions can
usefully include the following:
1. Inclusion of QSARs: The fundamental point is that
REACH requires the use of all available data, including
predictions generated by QSAR models, and ECHA
includes the use of QSARs in its basic guidance.
2. Specificity of purpose: REACH identifies different
assessments to be carried out in order to register, classify
or prioritise chemical substances, and those different reg-
ulatory tasks make different demands for evidence. Stake-
holder discussions of the use of QSAR models should
t h e r e f o r et a k ec a r et ob es p e c i f i ca b o u tt h er e g u l a t o r y
purpose and requirements being addressed.
3. Specificity of the model used: As ECHA makes expli-
cit in their case-by-case policy, the acceptance of the use
of a QSAR model for one chemical and one regulatory
function does not imply likely acceptance for another.
Models have to be understood as being specific to parti-
cular endpoints and particular domains of applicability,
and so care has to be taken when selecting models to use
in a particular evaluation.
4. Weight of evidence:T h ef o c u so ni n n o v a t i o na n d
the use of a range of sources requires industry (or their
consultants) to shift from using a single in vivo test
towards using a range of complementary sources of evi-
dence within a ‘weight of evidence’ approach.
5. Explicit uncertainty: All evaluations of chemical
toxicity inevitably contain uncertainty, whether pro-
duced by in vivo, in vitro or in silico models. The recog-
nition of this uncertainty, and the use of complementary
models and other sources of information to address it,
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ment or for other purposes.
6. Transparency: The regulatory acceptance of QSAR
models requires clear documentation both of the model
and of the way it has been used, sufficient to enable the
regulator to conduct an independent review of the
evidence.
As specific case studies become available, it will be pos-
sible to learn from them - while of course recognising
that regulatory acceptance is explicitly case-by-case,s o
that the acceptance or rejection of these individual uses
of QSAR models should not be over-generalised.
Future debate needs to clarify the acceptable uncer-
tainty in data from QSAR models across the different
regulatory functions. (Studies have been done on this
[21].) Decisions involve both scientific and political jud-
gements, so the debate should involve all stakeholders.
Acceptable uncertainty will be specific to particular eva-
luations and chemicals, perhaps because of their level of
toxicity or exposure levels or because of the proximity to
the regulatory decision point or simply the risk of being
wrong; it will be specific to particular endpoints, given
their different levels of impact. Discussions of acceptable
uncertainty need to acknowledge and approximate to the
levels of uncertainty that are viewed as acceptable or
inevitable within experimental values for that endpoint.
In QSAR modelling, the complexity of both the mole-
cular structures and the biological activities under inves-
tigation is huge, and different approximations and
assumptions are inevitably necessary. Clearly no single
model or platform can provide all the predictions needed.
Even for particular chemicals and endpoints, our prefer-
ence is towards the use of multiple models within a strat-
egy that is capable of utilising what each model can offer.
This requires a reshaping of the common procedure
to evaluate chemical data, but it is exactly in line with
the ‘weight of evidence’ approach advocated by ECHA
and within REACH, where uncertainty is reduced by the
complementary use of different models or methods.
I nt h en e a rf u t u r eah u g ea m o u n to fd a t aw i l lb e c o m e
available, including the data produced by the Tox21 [19]
and ToxCast [20] initiatives. To make use of this unpre-
cedented amount of data, new tools are necessary. It is
wise now to develop the debate on the suitable integra-
tion of QSAR models within a broader process of eva-
luation of chemical properties, especially within a
‘weight of evidence’ approach.
Acknowledgements and Funding
We acknowledge the financial contribution of the EC project ORCHESTRA
(number 226521).
Author details
1Istituto di Ricerche Farmacologiche “Mario Negri”, Via La Masa 19, 20156,
Milano, Italy.
2PublicSpace Ltd, Bletherbeck House, Ulverston, LA12 8DB, UK.
3Department of Electronics and Information, Politecnico di Milano, Piazza L.
da Vinci 32, 20133, Milano, Italy.
4Symlog, 262 rue St Jacques, 75005, Paris,
France.
5CentroReach, Via G. da Procida, 11, 20149, Milano, Italy.
6Interdisciplinary Research Unit on Risk Governance and Sustainable
Technology Development, University of Stuttgart, Seidenstraße 36, 70174,
Stuttgart, Germany.
Authors’ contributions
EB prepared a first draft, which was discussed with all authors. SP and EB
further developed the article in the light of external peer reviews.
Competing interests
The authors declare that they have no competing interests.
Received: 20 July 2011 Accepted: 7 October 2011
Published: 7 October 2011
References
1. ECHA: Guidance in a nutshell: Registration data and dossier handling.
2009, 14 & 19 [http://guidance.echa.europa.eu/docs/guidance_document/
nutshell_guidance.pdf].
2. Benfenati E, Ed: Quantitative structure-activity relationships (QSAR) for
pesticides regulatory purposes Amsterdam: Elsevier; 2007.
3. Regulation (EC) No 1907/2006: REACH - Registration, Evaluation,
Authorisation and Restriction of Chemicals.[http://ec.europa.eu/enterprise/
sectors/chemicals/reach/index_en.htm].
4. Roncaglioni A, Benfenati E: In silico-aided prediction of biological
properties of chemicals: oestrogen receptor-mediated effects. Chem Soc
Rev 2008, 37:441-450.
5. ECHA: Practical guide 5: How to report (Q)SAR. 2009, 2-4[http://echa.
europa.eu/doc/publications/practical_guides/pg_report_qsars.pdf].
6. AMBIT software:[http://ambit.sourceforge.net/].
7. Cassano A, Manganaro A, Martin T, Young Y, Piclin N, Pintore M, Bigoni D,
Benfenati E: The CAESAR models for developmental toxicity. Chemistry
Central Journal 2010, 4(Suppl 1):S4.
8. OECD: Environment Directorate. Validation of (Q)SAR models.[http://
www.oecd.org/dataoecd/33/37/37849783.pdf].
9. ECHA: Guidance on information requirements and chemical safety
assessment: Chapter R.6: QSARs and grouping of chemicals. 2008, 12-13
[http://guidance.echa.europa.eu/docs/guidance_document/
information_requirements_r6_en.pdf].
10. ECHA: Practical Guide 10. How to avoid unnecessary testing on animals.
2010 [http://echa.europa.eu/doc/publications/practical_guides/
pg_10_avoid_animal_testing_en.pdf].
11. Benfenati E: The CAESAR project for in silico models for the REACH
legislation. Chemistry Central Journal 2010, 4(Suppl 1):11.
12. Lombardo A, Roncaglioni A, Boriani E, Milan C, Benfenati E: Assessment
and validation of the CAESAR predictive model for bioconcentration
factor (BCF) in fish. Chemistry Central Journal 2010, 4(Suppl 1):S1.
13. Ferrari T, Gini G: An open source multistep model to predict
mutagenicity from statistical analysis and relevant structural alerts.
Chemistry Central Journal 2010, 4(Suppl 1):S2.
14. Fjodorova N, Vracko M, Novic M, Roncaglioni A, Benfenati E: New public
QSAR model for carcinogenicity. Chemistry Central Journal 2010, 4(Suppl
1):S3.
15. Chaudhry Q, Piclin N, Cotterill J, Pintore M, Price NR, Chrétien JR,
Roncaglioni A: Global QSAR models of skin sensitisers for regulatory
purposes. Chemistry Central Journal 2010, 4(Suppl 1):S5.
16. Zhu H, Martin TM, Young DM, Tropsha A: Combinatorial QSAR Modeling
of Rat Acute Toxicity by Oral Exposure. Chem Res Toxicol 2009,
22:1913-1921.
17. Zhu H, Tropsha A, Fourches D, Varnek A, Papa E, Gramatica P, Oberg T,
Dao P, Cherkasov A, Tetko IV: Combinatorial QSAR modeling of chemical
toxicants tested against Tetrahymena pyriformis. J Chem Inf Model 2008,
48:766-784.
18. Sushko I, Novotarskyi S, Körner R, Pandey AK, Cherkasov A, Li J, Gramatica P,
Hansen K, Schroeter T, Müller KR, Xi L, Liu H, Yao X, Öberg T, Hormozdiari F,
Dao P, Sahinalp C, Todeschini R, Polishchuk P, Artemenko A, Kuz’min V,
Martin TM, Young DM, Fourches D, Muratov E, Tropsha A, Baskin I,
Horvath D, Marcou G, Muller C, Varnek A, Prokopenko VV, Tetko IV:
Applicability domains for classification problems: benchmarking of
Benfenati et al. Chemistry Central Journal 2011, 5:58
http://journal.chemistrycentral.com/content/5/1/58
Page 10 of 11distance to models for AMES mutagenicity set. J Chem Inf Model 2010,
50:2094-2111.
19. Tox21 Research Program. [http://www.epa.gov/ncct/Tox21/].
20. ToxCast™: Screening Chemicals to Predict Toxicity Faster and Better.
[http://www.epa.gov/ncct/toxcast/].
21. Eriksson L, Jaworska J, Worth AP, Cronin MT, McDowell RM, Gramatica P:
Methods for Reliability and Uncertainty Assessment and for Applicability
Evaluations of Classification- and Regression-Based QSARs. Environ Health
Perspect 2003, 111:1361-1375.
doi:10.1186/1752-153X-5-58
Cite this article as: Benfenati et al.: The acceptance of in silico models
for REACH: Requirements, barriers, and perspectives. Chemistry Central
Journal 2011 5:58.
Open access provides opportunities to our 
colleagues in other parts of the globe, by allowing 
anyone to view the content free of charge.
Publish with ChemistryCentral and every
scientist can read your work free of charge
W. Jeffery Hurst, The Hershey Company.
available free of charge to the entire scientific community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours     you keep the copyright
Submit your manuscript here:
http://www.chemistrycentral.com/manuscript/
Benfenati et al. Chemistry Central Journal 2011, 5:58
http://journal.chemistrycentral.com/content/5/1/58
Page 11 of 11